home / stock / lbtsf / lbtsf short
Short Information | Almirall Sa Ord (OTCMKTS:LBTSF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 33,465 |
Total Actual Volume | 33,465 |
Short Trends | |
---|---|
Cover Days | 0 |
Short Days | 20 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 1,673 |
Average Short Percentage | 100.00% |
Is there a LBTSF Short Squeeze or Breakout about to happen?
See the LBTSF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
04-01-2024 | $0 | $9.51 | $0 | $0 | 6 | 6 | 100% |
09-13-2023 | $10.18 | $10.18 | $10.18 | $10.18 | 100 | 100 | 100% |
07-05-2023 | $0 | $8.85 | $0 | $0 | 34 | 34 | 100% |
06-21-2023 | $8.85 | $8.85 | $8.85 | $8.85 | 400 | 400 | 100% |
04-24-2023 | $0 | $9.68 | $0 | $0 | 25,000 | 25,000 | 100% |
12-01-2022 | $9.68 | $9.68 | $9.68 | $9.68 | 106 | 106 | 100% |
09-09-2022 | $9.28 | $9.28 | $9.28 | $9.28 | 1,000 | 1,000 | 100% |
05-06-2022 | $12.29 | $12.29 | $12.29 | $12.29 | 400 | 400 | 100% |
03-25-2022 | $13.85 | $13.85 | $13.85 | $13.85 | 100 | 100 | 100% |
11-29-2021 | $12.5 | $12.5 | $12.5 | $12.5 | 500 | 500 | 100% |
10-08-2021 | $15.3 | $15.3 | $15.3 | $15.3 | 200 | 200 | 100% |
04-07-2021 | $15 | $15 | $15 | $15 | 1,000 | 1,000 | 100% |
04-06-2021 | $15.1 | $15.2 | $15.2 | $15.1 | 1,300 | 1,300 | 100% |
10-28-2020 | $10.6 | $10.6 | $10.6 | $10.6 | 1,000 | 1,000 | 100% |
10-05-2020 | $12.3 | $12.3 | $12.3 | $12.3 | 571 | 571 | 100% |
08-04-2020 | $11.3 | $11.3 | $11.3 | $11.3 | 1,041 | 1,041 | 100% |
01-27-2020 | $15.96 | $15.96 | $15.96 | $15.96 | 100 | 100 | 100% |
01-22-2020 | $N/A | $16.90 | $N/A | $N/A | 11 | 11 | 100% |
01-17-2020 | $N/A | $16.90 | $N/A | $N/A | 25 | 25 | 100% |
01-16-2020 | $16.90 | $16.90 | $16.90 | $16.90 | 571 | 571 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Almirall Sa Ord Company Name:
LBTSF Stock Symbol:
OTCMKTS Market:
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutations ZKN-013 is a phase I ready oral therapy designed to overcome nonsense mutations that cause a premature stop codon re...
Almirall obtains exclusive global rights to develop and commercialize NN-8828 for use in several fields, including immune inflammatory dermatological diseases NN-8828 is an IL-21 blocker which inhibits the pathophysiological functions induced by this cytokine in several immune-modulated d...
Almirall’s Full-Year 2023 Results Company revenue growth driven by the strong performance of the European Dermatology business (+17% year-on-year) based on key growth divers and new launches: Ilumetri ® growing sales at 33.5% year-on-year; Klisyri ® strong sales g...